Research Grant: Myelofibrosis (Momelotinib)

Myelofibrosis (MF) Combinations:
Combination of MMB with agents (1L or as ‘add-on’) with potential for disease modification, not limited to:
• Anti-HJV (e.g., DISC-0974)
• BET inhibitors
• Anti-CALR therapies
• LSD1 inhibitors (e.g. bomedemstat)
• MDM2 inhibitors (e.g., Navtemadlin)
• PIM1 inhibitors (e.g., TP-3654)
• Telomerase inhibitors (e.g., Imetelstat)
• TGFb modulators (e.g., KER-050)
• XPO1 inhibitors (e.g., Selinexor)

Note: Proposals to address other hematologic malignancies may be considered for those with extraordinary scientific rationale (case-by-case)

• Chronic graft-vs-host-disease